Betaxolol
Administration
- Type: Beta blocker
- Dosage Forms: tablet, ophthalmic solution, ophthalmic suspension
- Dosage Stregths: tablet: 10 mg, 20 mg; ophthalmic solution: 0.5%; ophthalmic suspension: 0.25%
- Routes of Administration: PO, ophthalmic
- Common Trade Names: Kerlone, Betoptic, Betoptic S
Adult Dosing
- 5-80 mg PO daily
- 1-2 drops in affected eye BID
Pediatric Dosing
Safety/efficacy of oral forms and 0.5% solution not established in peds
- 0.25% suspension: 1 drop in affected eye BID
Special Populations
- Pregnancy Rating: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.
- Lactation risk: L3; Safety unknown
- Severe renal impairment: Start at 5mg PO daily, increase by 5mg/day q2wk to max daily dose 20mg
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Sinus bradycardia, 2nd or 3rd degree AV block, sick sinus syndrome (without pacemaker)
- Decompensated heart failure, cardiogenic shock
- Untreated pheochromocytoma
- Avoid abrupt withdrawal
Adverse Reactions
Serious
- CHF
- Severe bradycardia, heart block
- Angina exacerbation, ventricular arrythmia, or MI with abrupt discontinuation
- Bronchospasm
- Hypersensitivity reaction
- Psoriasis exacerbation, lupus erythematosus, Raynaud's phenomenon
Common
- Bradycardia, chest pain
- Headache, dizziness, fatigue
- Dyspepsia, diarrhea
- Arthralgia
- URI, pharyngitis
- Dyspnea
Pharmacology
- Half-life: 14-22 hr
- Metabolism: Liver extensively; CYP450: Unknown
- Excretion: Urine > 80% (15% unchanged)
Mechanism of Action
- Selectively antagonizes beta-1 adrenergic receptors.
Comments
See Also
- Beta-blockers
References
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.